Prospective monitoring of prostate specific membrane antigen–positive biochemically recurrent prostate cancer (PSMA+ BCR): Preliminary data from 6-month PSMA follow-up.Ravi A. Madan, Peter L. Choyke, Melissa L. Abel et al.|Journal of Clinical Oncology|2025Cited by 2
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).Mohammad Atiq, Ravi A. Madan, Liza Lindenberg et al.|Journal of Clinical Oncology|2023Cited by 0
Willingness of patients with biochemically recurrent prostate cancer (BCR) with positive 18F-dcfpyl PET/CT PSMA to monitor without treatment.Monique Williams, Ravi A. Madan, Amy Hankin et al.|Journal of Clinical Oncology|2024Cited by 0
Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.Ravi A. Madan, Peter L. Choyke, Melissa L. Abel et al.|Journal of Clinical Oncology|2025Cited by 0
Abstract PR008: Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)Melissa L. Abel, Ravi A. Madan, Aanika Warner et al.|Cancer Research|2026Cited by 0